Next Article in Journal
Lipotoxicity in Kidney, Heart, and Skeletal Muscle Dysfunction
Next Article in Special Issue
Impact of Magnesium Supplementation in Muscle Damage of Professional Cyclists Competing in a Stage Race
Previous Article in Journal
A Dietary Intervention with Reduction of Starch and Sucrose Leads to Reduced Gastrointestinal and Extra-Intestinal Symptoms in IBS Patients
Previous Article in Special Issue
The Association between Dietary Magnesium Intake and Magnetic Resonance Parameters for Knee Osteoarthritis

Predicting and Testing Bioavailability of Magnesium Supplements

Department of Movement and Sports Sciences, Ghent University, 9000 Ghent, Belgium
Laboratory of Pharmaceutical Technology, Ghent University, 9000 Ghent, Belgium
Author to whom correspondence should be addressed.
Nutrients 2019, 11(7), 1663;
Received: 11 June 2019 / Revised: 15 July 2019 / Accepted: 18 July 2019 / Published: 20 July 2019
(This article belongs to the Special Issue Dietary Magnesium for Health and Diseases)
Despite the presumption of the beneficial effects of magnesium supplementation, little is known about the pharmacokinetics of different magnesium formulations. We aimed to investigate the value of two in vitro approaches to predict bioavailability of magnesium and to validate this in subsequent in vivo testing. In vitro assessment of 15 commercially available magnesium formulations was performed by means of a Simulator of the Human Intestinal Microbial Ecosystem (SHIME®) and by dissolution tests. Two magnesium formulations with contrasting bioavailability prediction from both in vitro tests (best vs. worst) were selected for in vivo testing in 30 subjects. In vivo bioavailability was compared following one acute ingestion by monitoring blood magnesium concentrations up to 6 h following intake. The in vitro tests showed a very wide variation in absorption and dissolution of the 15 magnesium products. In the in vivo testing, a significant different serum magnesium absorption profile was found up to 4 h following supplement ingestion for the two supplements with opposing in vitro test results. Moreover, maximal serum magnesium increase and total area under the curve were significantly different for both supplements (+6.2% vs. +4.6% and 6.87 vs. 0.31 mM.min, respectively). Collectively, poor bioaccessibility and bioavailability in the SHIME model clearly translated into poor dissolution and poor bioavailability in vivo. This provides a valid methodology for the prediction of in vivo bioavailability and effectiveness of micronutrients by specific in vitro approaches. View Full-Text
Keywords: Magnesium; supplements; bioaccessibility; bioavailability Magnesium; supplements; bioaccessibility; bioavailability
Show Figures

Figure 1

MDPI and ACS Style

Blancquaert, L.; Vervaet, C.; Derave, W. Predicting and Testing Bioavailability of Magnesium Supplements. Nutrients 2019, 11, 1663.

AMA Style

Blancquaert L, Vervaet C, Derave W. Predicting and Testing Bioavailability of Magnesium Supplements. Nutrients. 2019; 11(7):1663.

Chicago/Turabian Style

Blancquaert, Laura, Chris Vervaet, and Wim Derave. 2019. "Predicting and Testing Bioavailability of Magnesium Supplements" Nutrients 11, no. 7: 1663.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop